Positive outcomes for apalutamide in the treatment of mHSPC

According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …

Race and survival of men after docetaxel-based treatment for mCRPC

A new paper in the Journal of Clinical Oncology has just reported that the overall survival (OS) of black and white men diagnosed with metastatic castration-resistant prostate cancer (mCRPC) seems to be near to identical after treatment with docetaxel or a docetaxel-containing regimen. … READ MORE …

Survival of men with metastatic, castration-resistant prostate cancer

There has been regular discussion here and elsewhere about the degree to which new forms of therapy have impacted patient survival since the original approval of docetaxel for treatment of metastatic, castration-resistant  prostate cancer (mCRPC). … READ MORE …

Lutetium-177 PSMA-617 in Phase III (VISION) trial for treatment of mCRPC

We have just been appraised of a randomized, double-blind, multi-center, Phase III clinical trial of the targeted, radiolabeled agent 177Lu-PSMA-617 (a form of “radioligand” therapy) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

ODM-201 meets Phase III goal in treatment of nmCRPC

Like other, similar drugs before it, ODM-201 — now properly known by the generic name darolutamide — has apparently hit the primary goal of metastasis-free survival in the Phase III ARAMIS trial, as announced yesterday by Bayer and Orion. … READ MORE …

I-131-MIP-1095 to enter randomized, Phase II clinical trial

As we reported last year, a new radiopharmaceutical has entered the pack. … READ MORE …

Results of PLATO trial published in JCO

The results of the PLATO trial have just been published in the Journal of Clinical Oncology (JCO). … READ MORE …